-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Kailaiying issued an announcement on the evening of October 24, stating that the company’s wholly-owned subsidiary, Kainuo Pharmaceutical, intends to acquire 100% of the shares held by the original shareholders of Yipu Kenuo with its own funds of 136 million yuan.
The purpose of this acquisition is mainly for Enhance the clinical research service section of Kailaiying
.
Kailaiying is a one-stop integrated service provider of CDMO (Customized Pharmaceutical Development and Production) serving the development and production of new drugs.
Since its listing in 2016, the company's performance has maintained rapid growth
.
In the first half of 2021, Kailaiying's operating income and net profit were 1.
76 billion yuan and 429 million yuan, an increase of 39.
04% and 36.
03% year-on-year, and continued to maintain a rapid growth trend
.
Yipu Kenuo is a company focused on clinical data management and statistical services, dedicated to providing pharmaceutical companies and CRO companies with statistical design, CRF design, EDC creation, data cleaning, data set generation, and clinical trial report writing.
And submit one-stop professional services of mathematics
.
The company's core team has worked in Novo Nordisk, Pfizer, AstraZeneca, Parexel, Covance, PPD and other large global pharmaceutical companies or CRO companies, and has rich experience in digital business and management
.
Kailaiying said that this acquisition can enhance Kailaiying's clinical research service segment-Kailuo Pharmaceutical's professional capabilities and service capabilities in data management and biostatistics.
It has improved the entire business chain and is a technology leader for Kailuo Pharmaceutical.
An important step for a clinical CRO company
.
It is reported that after the completion of this acquisition, the two parties will give full play to their respective professional advantages and realize a strong combination of CRO business modules with different expertise, which is conducive to building a high-level industrial service chain, comprehensively improving integrated service capabilities, and achieving good business synergy.
, Lay a solid foundation for Kainuo Pharmaceutical's global layout
.
With the rapid promotion of the clinical research service sector and the continuous improvement of its competitiveness, in the future, Kailai Ying can better provide customers with CDMO + clinical CRO services, increase the stickiness with many customers, and gradually become a part of the innovative drug R&D and production chain.
An indispensable part to achieve sustained and rapid development
.
In fact, before this merger, Kailaiying also actively deployed outbound mergers and acquisitions in the CRO field to continuously improve its competitiveness
.
For example, in September 2020, Kailaiying announced that it plans to acquire 100% equity of Guanqin Pharmaceutical for RMB 30 million
.
It is understood that Guanqin Pharmaceutical is also one of the domestic CRO giants
.
In the pre-clinical field, Guanqin Pharmaceutical has served more than 150 pharmaceutical companies and more than 200 new drug R&D projects.
In terms of clinical research, it has undertaken more than 200 clinical trial services in different stages
.
The 2020 annual report shows that Kailaiying's clinical research services have made rapid progress through the merger and integration with Guanqin Pharmaceutical and the exploration of new business models
.
The revenue in 2020 will reach 48 million yuan .
It is worth mentioning that this time Gloria also signed a performance betting agreement with the original shareholders of Yipu Ke Nuo.
Yipu Ke Nuo will realize the deduction of non-recurring gains and losses confirmed by the audit in 2022, 2023 and 2024.
The net profit should be no less than 9 million yuan, 12 million yuan, and 15 million yuan respectively
.
Judging from the current profit situation of Yipu Kenuo, the company's revenue in 2020 will be 21.
775 million yuan, and the net profit will be 2.
93 million yuan; in the first half of 2021, it will achieve 12.
765 million yuan in revenue and 574,000 yuan in net profit
.
The industry believes that in order to complete the performance gambling target, there may still be some difficulties in Yipu Ke Nuo
.
The purpose of this acquisition is mainly for Enhance the clinical research service section of Kailaiying
.
Kailaiying is a one-stop integrated service provider of CDMO (Customized Pharmaceutical Development and Production) serving the development and production of new drugs.
Since its listing in 2016, the company's performance has maintained rapid growth
.
In the first half of 2021, Kailaiying's operating income and net profit were 1.
76 billion yuan and 429 million yuan, an increase of 39.
04% and 36.
03% year-on-year, and continued to maintain a rapid growth trend
.
Yipu Kenuo is a company focused on clinical data management and statistical services, dedicated to providing pharmaceutical companies and CRO companies with statistical design, CRF design, EDC creation, data cleaning, data set generation, and clinical trial report writing.
And submit one-stop professional services of mathematics
.
The company's core team has worked in Novo Nordisk, Pfizer, AstraZeneca, Parexel, Covance, PPD and other large global pharmaceutical companies or CRO companies, and has rich experience in digital business and management
.
Kailaiying said that this acquisition can enhance Kailaiying's clinical research service segment-Kailuo Pharmaceutical's professional capabilities and service capabilities in data management and biostatistics.
It has improved the entire business chain and is a technology leader for Kailuo Pharmaceutical.
An important step for a clinical CRO company
.
It is reported that after the completion of this acquisition, the two parties will give full play to their respective professional advantages and realize a strong combination of CRO business modules with different expertise, which is conducive to building a high-level industrial service chain, comprehensively improving integrated service capabilities, and achieving good business synergy.
, Lay a solid foundation for Kainuo Pharmaceutical's global layout
.
With the rapid promotion of the clinical research service sector and the continuous improvement of its competitiveness, in the future, Kailai Ying can better provide customers with CDMO + clinical CRO services, increase the stickiness with many customers, and gradually become a part of the innovative drug R&D and production chain.
An indispensable part to achieve sustained and rapid development
.
In fact, before this merger, Kailaiying also actively deployed outbound mergers and acquisitions in the CRO field to continuously improve its competitiveness
.
For example, in September 2020, Kailaiying announced that it plans to acquire 100% equity of Guanqin Pharmaceutical for RMB 30 million
.
It is understood that Guanqin Pharmaceutical is also one of the domestic CRO giants
.
In the pre-clinical field, Guanqin Pharmaceutical has served more than 150 pharmaceutical companies and more than 200 new drug R&D projects.
In terms of clinical research, it has undertaken more than 200 clinical trial services in different stages
.
The 2020 annual report shows that Kailaiying's clinical research services have made rapid progress through the merger and integration with Guanqin Pharmaceutical and the exploration of new business models
.
The revenue in 2020 will reach 48 million yuan .
It is worth mentioning that this time Gloria also signed a performance betting agreement with the original shareholders of Yipu Ke Nuo.
Yipu Ke Nuo will realize the deduction of non-recurring gains and losses confirmed by the audit in 2022, 2023 and 2024.
The net profit should be no less than 9 million yuan, 12 million yuan, and 15 million yuan respectively
.
Judging from the current profit situation of Yipu Kenuo, the company's revenue in 2020 will be 21.
775 million yuan, and the net profit will be 2.
93 million yuan; in the first half of 2021, it will achieve 12.
765 million yuan in revenue and 574,000 yuan in net profit
.
The industry believes that in order to complete the performance gambling target, there may still be some difficulties in Yipu Ke Nuo
.
